NasdaqGM - Delayed Quote USD

GH Research PLC (GHRS)

12.08

-0.49

(-3.90%)

At close: May 29 at 4:00:01 PM EDT

11.81

-0.27

(-2.24%)

After hours: May 29 at 7:09:08 PM EDT

GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting

DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Pharmaceutical Pipeline Presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP) in Arizona, United States from May 27 – 30, where Professor Michael E. Thase, MD, Professor of Psychiatry, Perelman School of M

GlobeNewswire 14 days ago

GHRS
-3.90%
Here's Why We're Not Too Worried About GH Research's (NASDAQ:GHRS) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 19 days ago

GHRS
-3.90%
Psychedelic: Compass, GH Research, MindMed report quarterly earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a patent grant and study results. Q1 EARNINGS: On Thursday, Compass Pathways (CMPS) reported a first quarter loss per share of (24c), which compared to analyst estimates of a loss per share of (49c). The company said cash and cash equivalents were $260.1M as of March 31, compared with $165.1M as of December 31. Compass also guided to full year 2025 net cash used in operatin

TipRanks 20 days ago

CYBN

GHRS
-3.90%

CMPS
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates

Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents, other financial assets and marketable securities of $315.3 million as of March 31, 2025 DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment

GlobeNewswire 21 days ago

GHRS
-3.90%
What Makes GH Research (GHRS) a New Buy Stock

GH Research (GHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 24 days ago

GHRS
-3.90%
Psychedelic: Exclusive talk with biotech company Clearmind Medicine

In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine (CMND), a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights: PSYCHEDELIC PHARMA: Clearmind is a clinical-stage biotech company that aims to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods

TipRanks 2 months ago

CMND

ATAI

GHRS
-3.90%
Psychedelic: atai Life Sciences, NRx report quarterly results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a collaboration LOI and a study publication. EARNINGS: On Monday, atai Life Sciences (ATAI) reported a fourth quarter loss per share of (24c) on revenue loss of ($5,000), which compared to analyst estimates of a loss per share of (15c) and revenue of $18,000 for the same period last year. As of December 31, the company had cash, cash equivalents, restricted cash and short-t

TipRanks 2 months ago

CYBN

ATAI

CMND
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement. ATAI DOSES FIRST PATIENT IN PHASE 2 VLS-01 TRIAL: atai Life Sciences (ATAI) announced Tuesday that the first patient has been dosed in the Phase 2 Elumina trial of VLS-01, atai’s proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine applied to the buccal surface, in people suffering from tre

TipRanks 2 months ago

ATAI

MNMD

CMND
Guggenheim starts GH Research at Buy, sees long-term upside potential

Guggenheim initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target The firm’s thesis on GH is based around the belief that rapid-acting psychedelics like 5-MeO-DMT have the potential to transform the treatment resistant depression treatment landscape, the analyst tells investors in a research note. The firm added that, with pivotal milestones in the sector coming over the next 6-12 months and an update on the clinical hold anticipated this year, it believes GH is well-pos

TipRanks 2 months ago

GHRS
-3.90%
Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in the biotech space. There will always be […]

Insider Monkey 2 months ago

GHRS
-3.90%
GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other psychedelic stocks. The Therapeutic Potential and Investment Boom in Psychedelic Medicine In contrast to drugs like cocaine or marijuana, psychedelics are […]

Insider Monkey 2 months ago

GHRS
-3.90%
Psychedelic: GH Research, Compass Pathways report earnings results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, an analyst initiation and patent issuance. EARNINGS: On Thursday, GH Research (GHRS) reported a FY24 loss per share of (75c), which compared to analyst estimates of loss per share of (80c). The company also reported cash, cash equivalents, other financial assets and marketable securities at $182.6M as of December 31, compared to cash, cash equivalents, other financial asset

TipRanks 2 months ago

QNTM

ENVB

CYBN
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UKFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents, other financial assets and marketable securities of $182.6 million as of December 31, 2024Net cash proceeds of an additional $139.8 m

GlobeNewswire 2 months ago

GHRS
-3.90%
GH Research PLC (GHRS): Among the Best Performing Small Cap Stocks So Far In 2025

We recently compiled a list of the 12 Best Performing Small Cap Stocks So Far in 2025. In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other small cap stocks. On February 14, Stacey Sears, portfolio manager at Emerald Advisors, joined ‘Squawk Box’ on CNBC […]

Insider Monkey 3 months ago

GHRS
-3.90%
GH Research PLC's (NASDAQ:GHRS) Top Key Executive Florian Schonharting is the most upbeat insider, and their holdings increased by 31% last week

Key Insights GH Research's significant insider ownership suggests inherent interests in company's expansion A total of...

Simply Wall St. 3 months ago

GHRS
-3.90%
GHRS Stock Rallies 55% in a Week: Here's What You Should Know

GH Research stock soars 55% in a week after the company meets the primary goal in a mid-stage depression study of its lead candidate, GH001.

Zacks 3 months ago

GHRS
-3.90%
GH Research Announces Pricing of $150 Million Public Offering

DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of its previously announced underwritten public offering in the United States of 10,000,000 ordinary shares at a public offering price of $15.00 per share for total gross proceeds of approximately $150 million. All of the ordinary shares are being

GlobeNewswire 3 months ago

GHRS
-3.90%
GH Research Announces Proposed Public Offering

DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the commencement of an underwritten public offering in the United States of $150 million of ordinary shares. All of the ordinary shares are to be offered by GH Research PLC. In addition, GH Research PLC intends to grant the underwriters an option to purchase u

GlobeNewswire 3 months ago

GHRS
-3.90%
Shares of psychedelics biotech nearly double on depression data

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was fast and effective in a treatment-resistant depression trial.

BioPharma Dive 3 months ago

GHRS
-3.90%
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group (p<0.0001)All other secondary endpoints were met with clinically and statistically significant improvements on Day 8, compared with placeboDuring the double-blind part, GH001 was well tolerat

GlobeNewswire 3 months ago

GHRS
-3.90%

Performance Overview

Return	GHRS	S&P 500 (^GSPC)
YTD	+72.57%	+0.52%
1-Year	-6.57%	+12.25%
3-Year	+25.96%	+42.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

GH Research PLC (GHRS)

GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting

Here's Why We're Not Too Worried About GH Research's (NASDAQ:GHRS) Cash Burn Situation

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates

What Makes GH Research (GHRS) a New Buy Stock

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai Life Sciences, NRx report quarterly results

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

Guggenheim starts GH Research at Buy, sees long-term upside potential

Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025

GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025

Psychedelic: GH Research, Compass Pathways report earnings results

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

GH Research PLC (GHRS): Among the Best Performing Small Cap Stocks So Far In 2025

GH Research PLC's (NASDAQ:GHRS) Top Key Executive Florian Schonharting is the most upbeat insider, and their holdings increased by 31% last week

GHRS Stock Rallies 55% in a Week: Here's What You Should Know

GH Research Announces Pricing of $150 Million Public Offering

GH Research Announces Proposed Public Offering

Shares of psychedelics biotech nearly double on depression data

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

Performance Overview